Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Clinical trial NCT05241028 · RECRUITING

Trial details

NCT number: NCT05241028
Sponsor: Hebei Medical University Fourth Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2022-05-01
Primary completion: 2027-02-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.